These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16292363)

  • 1. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon.
    Milkiewicz P; Yim C; Pache I; Heathcote J
    Can J Gastroenterol; 2005 Nov; 19(11):677-8. PubMed ID: 16292363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injection site with generalized rash caused by pegylated interferon alpha 2a injection.
    Kawada K; Maeda N; Kobayashi S; Sowa J; Tsuruta D; Kawada N
    Dermatology; 2006; 212(1):82-3. PubMed ID: 16319482
    [No Abstract]   [Full Text] [Related]  

  • 3. Morbilliform drug eruption due to pegylated α-interferon can show complete regression after switching to non-pegylated interferon.
    Barut S; Yuksek J; Sezer E; Gunal O; Koseoglu D
    J Dermatol; 2011 May; 38(5):479-81. PubMed ID: 21352322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rash from hepatitis C treatment.
    Tang DM; Ward L
    Cleve Clin J Med; 2011 Jul; 78(7):472-4. PubMed ID: 21724930
    [No Abstract]   [Full Text] [Related]  

  • 5. Allergic sensitization to pegylated interferon-α results in drug eruptions.
    Meller S; Gerber PA; Kislat A; Hevezi P; Göbel T; Wiesner U; Kellermann S; Bünemann E; Zlotnik A; Häussinger D; Erhardt A; Homey B
    Allergy; 2015 Jul; 70(7):775-83. PubMed ID: 25831972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
    Venezia G; Licata A; Di Marco V; Craxì A; Almasio PL
    Dig Liver Dis; 2005 Nov; 37(11):882-5. PubMed ID: 16169301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon alpha-2B induced lupus in a patient with chronic hepatitis B virus infection: case report.
    Yilmaz S; Cimen KA
    Clin Rheumatol; 2009 Oct; 28(10):1241-3. PubMed ID: 19653058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug rash with eosinophilia and systemic symptoms due to telaprevir.
    Montaudié H; Passeron T; Cardot-Leccia N; Sebbag N; Lacour JP
    Dermatology; 2010; 221(4):303-5. PubMed ID: 20798484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection.
    Ji F; Li Z; Xue H; Liu L; Deng H
    South Med J; 2011 Feb; 104(2):140-2. PubMed ID: 21206334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon?
    Cottoni F; Bolognini S; Deplano A; Garrucciu G; Manzoni NE; Careddu GF; Montesu MA; Tocco A; Lissia A; Solinas A
    Acta Derm Venereol; 2004; 84(2):120-3. PubMed ID: 15206691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis.
    Sporea I; Popescu A; Sirli R; Golea O; Totolici C; Danila M; Vernic C
    World J Gastroenterol; 2006 Jul; 12(26):4191-4. PubMed ID: 16830372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
    Perry CM; Jarvis B
    BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thyroid dysfunction in patients with chronic hepatitis C treated with pegylated interferon alpha].
    Montero-Tinnirello J; de la Fuente-Aguado J; Rodríguez-Pecci MS; Fernández-Fernández FJ
    Rev Clin Esp; 2011 Sep; 211(8):436-8. PubMed ID: 21546017
    [No Abstract]   [Full Text] [Related]  

  • 18. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
    Hui CK; Lai LS; Lam P; Zhang HY; Fung TT; Lai ST; Wong WM; Lo CM; Fan ST; Leung N; Lau GK;
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1171-8. PubMed ID: 16611278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sarcoidosis induced by therapy with pegylated interferon alfa-2a].
    Bruch-Gerharz D; Reifenberger J
    Hautarzt; 2006 Apr; 57(4):317-35. PubMed ID: 16523277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.